Association of Race and Ethnicity With Initial Prescription of Antiretroviral Therapy Among People With HIV in the US.
暂无分享,去创建一个
A. Adimora | T. Sterling | M. Horberg | P. Rebeiro | E. Williams | K. Gebo | R. Lang | J. Eron | M. Silverberg | J. Edwards | A. Vines | M. Klein | K. Althoff | A. Mayor | S. Coburn | S. R. Cole | M. Gill | L. Zalla | Vincent C. Marconi | R. Moore | Peter F. Rebeiro
[1] David A. Drew,et al. Self-reported COVID-19 vaccine hesitancy and uptake among participants from different racial and ethnic groups in the United States and United Kingdom , 2022, Nature communications.
[2] C. Ladva,et al. Racial and Ethnic Disparities in Receipt of Medications for Treatment of COVID-19 — United States, March 2020–August 2021 , 2022, MMWR. Morbidity and mortality weekly report.
[3] Jessie K. Edwards,et al. Virologic outcomes among adults with HIV using integrase inhibitor-based antiretroviral therapy , 2021, AIDS.
[4] Richard D Moore,et al. Integrase Inhibitor Prescribing Disparities in the DC and Johns Hopkins HIV Cohorts , 2021, Open forum infectious diseases.
[5] Jessie K. Edwards,et al. Mortality Among Persons Entering HIV Care Compared With the General U.S. Population , 2021, Annals of Internal Medicine.
[6] N. Hessol,et al. Disparities in Integrase Inhibitor Usage in the Modern HIV Treatment Era: A Population-Based Study in a US City , 2021, Open forum infectious diseases.
[7] S. Bass,et al. Exploring the Engagement of Racial and Ethnic Minorities in HIV Treatment and Vaccine Clinical Trials: A Scoping Review of Literature and Implications for Future Research. , 2020, AIDS patient care and STDs.
[8] Richard D Moore,et al. Weight gain among treatment‐naïve persons with HIV starting integrase inhibitors compared to non‐nucleoside reverse transcriptase inhibitors or protease inhibitors in a large observational cohort in the United States and Canada , 2020, Journal of the International AIDS Society.
[9] J. Eron,et al. Increased Persistence of Initial Treatment for HIV Infection With Modern Antiretroviral Therapy , 2017, Journal of acquired immune deficiency syndromes.
[10] B. Lau,et al. Sex, Race, and HIV Risk Disparities in Discontinuity of HIV Care After Antiretroviral Therapy Initiation in the United States and Canada , 2017, AIDS patient care and STDs.
[11] Christopher H. Johnson,et al. Trends in Racial and Ethnic Disparities in Antiretroviral Therapy Prescription and Viral Suppression in the United States, 2009–2013 , 2016, Journal of acquired immune deficiency syndromes.
[12] B. Hunt,et al. Black:White Disparities in HIV Mortality in the United States: 1990–2009 , 2016, Journal of Racial and Ethnic Health Disparities.
[13] D. Podzamczer,et al. Brief Report: Dolutegravir Plus Abacavir/Lamivudine for the Treatment of HIV-1 Infection in Antiretroviral Therapy-Naive Patients: Week 96 and Week 144 Results From the SINGLE Randomized Clinical Trial , 2015, Journal of acquired immune deficiency syndromes.
[14] Jessie K. Edwards,et al. Ten-year Survival by Race/Ethnicity and Sex Among Treated, HIV-infected Adults in the United States. , 2015, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[15] J. Palmer,et al. Racism, segregation, and risk of obesity in the Black Women's Health Study. , 2014, American journal of epidemiology.
[16] S. Walmsley,et al. Dolutegravir plus abacavir-lamivudine for the treatment of HIV-1 infection. , 2013, The New England journal of medicine.
[17] Jennifer A. Pellowski,et al. A pandemic of the poor: social disadvantage and the U.S. HIV epidemic. , 2013, The American psychologist.
[18] Y. Yazdanpanah,et al. Durable Efficacy and Safety of Raltegravir Versus Efavirenz When Combined With Tenofovir/Emtricitabine in Treatment-Naive HIV-1–Infected Patients: Final 5-Year Results From STARTMRK , 2013, Journal of acquired immune deficiency syndromes.
[19] Richard D Moore,et al. U.S. Trends in Antiretroviral Therapy Use, HIV RNA Plasma Viral Loads, and CD4 T-Lymphocyte Cell Counts Among HIV-Infected Persons, 2000 to 2008 , 2012, Annals of Internal Medicine.
[20] A. Lleras-Muney,et al. Technological innovation and inequality in health , 2008, Demography.
[21] B. Agan,et al. Virologic Response Differences Between African Americans and European Americans Initiating Highly Active Antiretroviral Therapy With Equal Access to Care , 2009, Journal of acquired immune deficiency syndromes.
[22] Bruce G. Link,et al. Medical Advances and Racial/Ethnic Disparities in Cancer Survival , 2009, Cancer Epidemiology, Biomarkers & Prevention.
[23] D. Lauderdale,et al. Fundamental Cause Theory, Technological Innovation, and Health Disparities: The Case of Cholesterol in the Era of Statins∗ , 2009, Journal of health and social behavior.
[24] Richard D Moore,et al. Cohort profile: the North American AIDS Cohort Collaboration on Research and Design (NA-ACCORD). , 2007, International journal of epidemiology.
[25] S. Ettner,et al. Racial and ethnic disparities in access to physicians with HIV-related expertise , 2005, Journal of General Internal Medicine.
[26] S. Crystal,et al. Initiation and continuation of newer antiretroviral treatments among medicaid recipients with AIDS , 2001, Journal of General Internal Medicine.
[27] V. Stone. Physician contributions to disparities in HIV/AIDS care: The role of provider perceptions regarding adherence , 2005, Current HIV/AIDS reports.
[28] Richard D Moore,et al. Racial and Gender Disparities in Receipt of Highly Active Antiretroviral Therapy Persist in a Multistate Sample of HIV Patients in 2001 , 2005, Journal of acquired immune deficiency syndromes.
[29] Bruce G. Link,et al. “Fundamental Causes” of Social Inequalities in Mortality: A Test of the Theory∗ , 2004, Journal of health and social behavior.
[30] R. Weech-Maldonado,et al. Medicaid Managed Care and Racial Disparities in AIDS Treatment , 2004, Health care financing review.
[31] N. Sood,et al. The Link between Public and Private Insurance and Hiv-Related Mortality , 2002, Journal of health economics.
[32] H. Palacio,et al. Effect of Race and/or Ethnicity in Use of Antiretrovirals and Prophylaxis for Opportunistic Infection: A Review of the Literature , 2002, Public health reports.
[33] R. Chaisson,et al. Racial differences in the use of drug therapy for HIV disease in an urban community. , 1994, The New England journal of medicine.